About CDI

Clostridioides difficile infection (CDI) is associated with high burden of hospitalizations, morbidity, and mortality. The U.S. Centers for Disease Control and Prevention (CDC) estimated 223,900 cases in hospitalized patients, 12,800 deaths, and $1 billion in healthcare costs from CDI in 2017, qualifying CDI as an urgent threat in the agency’s 2019 Antibiotic/Antimicrobial Resistance Threats Report as an urgent threat.

The AGA hosted a multidisciplinary faculty to align on care for CDI patients on diagnostic and therapeutic approaches for the prevention and treatment of CDI, including the role of live biotherapeutic products.

The conference was supported by independent medical education grants from Ferring Pharmaceuticals, Nestlé Health Science, and Seres Therapeutics.